NEWS

Harvard scientist George Church, a pioneer of both DNA sequencing and gene editing, has been talking in the press for more than a decade about the possibility of bringing the extinct woolly mammoth back to life. It’s been the subject of magazine articles, books, and, of course, a TEDx talk. Now, it is the focus of a…

“Can you give me a thumbs up?” the surgeon asks Jerry Majetich, an Iraq War veteran, during a checkup this spring at a Boston hospital. “Can you make me a fist? And extend your fingers?” It is an odd, even jarring, series of requests to make of a patient whose right arm has been amputated…

Probenecid is already FDA approved and has potent antiviral properties against SARS-CoV-2 As COVID-19 cases continue to skyrocket across the U.S. and the world, few options are available for treating patients infected with the SARS-CoV-2. But new research from the University of Georgia offers hope for a viable therapeutic to combat the disease that has claimed…

Boehringer Ingelheim’s work to discover and develop innovative new therapeutics will now look to antibodies to attack and treat a wide range of diseases—but there’s a twist. Twist Biosciences, that is, with whom the company has formed a long-term partnership for therapeutic antibody discovery. Boehringer will look to Twist’s “Library of Libraries” of antibody sequences…

President Joe Biden on Thursday announced a set of ambitious plans to implement vaccine requirements for health facilities that receive federal funding, federal employers and contractors, and businesses with more than 100 employees in a bid to gain control over the worst wave of Covid-19 infections since last winter. The requirements are part of a…

The state’s Community Organized Relief Effort was able to go from zero field teams to 36 in just 60 days. The Community Organized Relief Effort in Georgia, better known as CORE, had a major operational challenge to coordinate all the logistical issues of setting up mobile vaccinations for COVID-19 across an entire state and managing dozens…